Lenire is now available in Sweden
It is estimated that one sixth of the Swedish population has some form of tinnitus. And the problem is on the rise as our modern lifestyles involve increased sound exposure, changing listening habits and noise1. Just last week, Swedish DJ Alesso posted how his severe tinnitus had caused him to cancel gigs.
Tinnitus is a complex neurological condition that causes people to experience sound without an external sound source. Estimates suggest that around 15% of the world’s adult population lives with tinnitus. Yet, it is still difficult to find treatment options with long-term efficacy in Sweden.
Lenire – a new device using bimodal neuromodulation to soothe tinnitus
Lenire® from Neuromod Devices is a bimodal neuromodulation device which works by delivering mild tongue pulses, through an intra-oral component called the ‘Tonguetip®’.
Tonguetip stimulation is combined with auditory stimulation through headphones to drive long-term changes in the brain. Lenire’s dual action stimulus is proven to provide long term relief from tinnitus 2.
Sweden is the latest location to make Lenire available, following successful launches in Denmark, Norway, Spain, Italy, Poland, Switzerland, and the UK. The US FDA awarded Lenire a De Novo Grant. FDA Approval made the groundbreaking device available in the US.
Lenire: Clinically Proven Tinnitus Treatment Device
Demonstrable safety and effectiveness in three large scale clinical trials contribute to Lenire’s demand. These trials featured over 600 patients with an overwhelming prevalence of tinnitus.
Lenire received FDA approval in the US in March 2023, based on the success of the large-scale controlled clinical trial TENT-A3 (Treatment Evaluation of Neuromodulation for Tinnitus – Stage A3).This trial showed that Lenire is more effective in providing relief from bothersome tinnitus than sound therapy alone, which was the trial control3. In 2024, the medical journal Nature Communications published the peer-reviewed results of Neuromod Devices’ TENT-A3.
A retrospective analysis of 220 US tinnitus patients has further demonstrated Lenire’s real-world effectiveness, with 91.5% of patients experiencing a clinically significant reduction in tinnitus after 12 weeks of treatment with Lenire and as many as 89.2% said they benefited from treatment with Lenire4.
New hope for patients with chronical tinnitus
“Tinnitus is a multifactorial symptom where specialised care and technology should be combined in treatment. With Lenire, I am very pleased to be able to offer patients with tinnitus a new innovative treatment option at our clinic,” says licenced audiologist Aylin Ågren at Audioteket Sweden.
From the Audioteket hearing centre in Stockholm, Lenire can be prescribed to patients from all over Sweden. Learn more by visiting
https://audiotek.se/
Lenire in the Media:
MedTechMagazine: Tungkittlande enhet ska lindra tinnitus – nu i Sverige (February 2025)
SVT: Här är hjälpmedlet som ska lindra tinnitus | SVT Nyheter (22 October 2024)
